Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery
Recruitment status was Recruiting
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, oxaliplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether giving fluorouracil and cisplatin together with radiation therapy is more effective than giving gemcitabine together with oxaliplatin in treating nonmetastatic biliary tract cancer.
PURPOSE: This randomized phase II/III trial is studying fluorouracil, cisplatin, and radiation therapy to see how well they work compared to gemcitabine and oxaliplatin in treating patients with nonmetastatic biliary tract cancer that cannot be removed by surgery.
Extrahepatic Bile Duct Cancer
Drug: gemcitabine hydrochloride
|Study Design:||Allocation: Randomized
Primary Purpose: Treatment
|Official Title:||Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract|
- Progression rate at 3 months [ Designated as safety issue: No ]
- Overall survival [ Designated as safety issue: No ]
- Toxicity [ Designated as safety issue: Yes ]
- Quality of life [ Designated as safety issue: No ]
- Biliary complication rate [ Designated as safety issue: No ]
- Duration of hospitalization [ Designated as safety issue: No ]
|Study Start Date:||October 2005|
|Estimated Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
- Compare the 3-month progression rate in patients with unresectable, nonmetastatic cancer of the biliary tract treated with fluorouracil, cisplatin, and radiotherapy vs gemcitabine hydrochloride and oxaliplatin. (phase II)
- Compare the overall survival of patients treated with these regimens. (phase III)
- Compare toxicities of these regimens in these patients. (phase II)
- Compare the quality of life at initial drainage (phase II) and overall (phase III) of patients treated with these regimens.
- Compare the biliary complication rate in patients treated with these regimens.
- Compare the duration of hospitalization of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease location (gallbladder vs intrahepatic biliary duct vs extrahepatic biliary duct). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo radiotherapy once daily, 5 days a week on days 1-33. Patients also receive fluorouracil IV continuously over 5 days once a week in weeks 1-5 and cisplatin IV over 15 minutes on days 1-4 and 29-32 (or days 1 or 2 and 29 or 30) in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive gemcitabine hydrochloride IV over 100 minutes and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and then every 3 months thereafter.
After completion of study therapy, patients are followed periodically for 2 years.
PROJECTED ACCRUAL: A total of 170 patients will be accrued for this study.
|Centre Hospitalier General||Recruiting|
|Belfort, France, 90000|
|Contact: Serge Fratte, MD 33-384-574-095 firstname.lastname@example.org|
|Centre Hospitalier Pierre Oudot||Recruiting|
|Bourgoin-Jallieu, France, 38300|
|Contact: Noel Stremsdoerfer, MD 33-4-7427-3011|
|Hopital Louis Pasteur||Recruiting|
|Colmar, France, 68024|
|Contact: Bernard Denis 33-3-8912-4097|
|Centre Hospitalier de Dax||Recruiting|
|Dax, France, 40100|
|Contact: Laure Gautier-Felizot 33-6-8591-9735|
|Hopital Du Bocage||Recruiting|
|Dijon, France, 21034|
|Contact: Laurent Bedenne, MD 33-3-8029-3750 email@example.com|
|Centre de Lutte Contre le Cancer Georges-Francois Leclerc||Recruiting|
|Dijon, France, 21079|
|Contact: Bruno Chauffert 33-3-8073-7506 firstname.lastname@example.org|
|Centre Hospitalier Departemental||Recruiting|
|La Roche Sur Yon, France, F-85025|
|Contact: Roger Faroux 33-2-5144-6168|
|C. H. Du Mans||Recruiting|
|Le Mans, France, 72037|
|Contact: Marie-Aude Coulon 33-2-4343-4343|
|CHU de la Timone||Recruiting|
|Marseille, France, 13385|
|Contact: Jean-Francois Seitz, MD 33-4-9138-6023|
|Centre Hospitalier General de Mont de Marsan||Recruiting|
|Mont-de-Marsan, France, 40000|
|Contact: Patrick Texereau, MD 33-5-5805-1164|
|CHR D'Orleans - Hopital de la Source||Recruiting|
|Orleans, France, 45100|
|Contact: Jean-Paul Lagasse 33-02-3651-4704|
|Paris, France, 75651|
|Contact: Julien Taieb, MD 33-1-4216-1023|
|Hopital Bichat - Claude Bernard||Recruiting|
|Paris, France, 75018|
|Contact: Thomas Aparicio 33-1-4025-7200 email@example.com|
|Centre Hospitalier Lyon Sud||Recruiting|
|Pierre Benite, France, 69495|
|Contact: Francoise Mornex, MD, PhD 33-478-864-253 firstname.lastname@example.org|
|Hopital Sebastopol, C.H.U. de Reims||Recruiting|
|Reims, France, 51092|
|Contact: Stephanie Lagarde 33-326-784-410|
|Centre Eugene Marquis||Recruiting|
|Rennes, France, 35062|
|Contact: Eveline Boucher, MD 33-2-9925-3180 email@example.com|
|Hopital Charles Nicolle||Recruiting|
|Rouen, France, 76031|
|Contact: Pierre Michel 33-2-3288-8260|
|Centre Hospitalier de Semur en Auxois||Recruiting|
|Semur en Auxois, France, 21140|
|Contact: Patenotte 33-3-8089-6464|
|Hopital Universitaire Hautepierre||Recruiting|
|Strasbourg, France, 67098|
|Contact: Palascak 33-388-127-682|
|Centre Hospitalier de Tarbes||Recruiting|
|Tarbes, France, 65013|
|Contact: Glibert 33-5-6251-5151|
|Principal Investigator:||Bruno Chauffert||Centre de Lutte Contre le Cancer Georges-Francois Leclerc|